These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 2872225)
1. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs. Lamberts SW; Zweens M; Verschoor L; del Pozo E J Clin Endocrinol Metab; 1986 Jul; 63(1):16-9. PubMed ID: 2872225 [TBL] [Abstract][Full Text] [Related]
2. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine. Chiodini PG; Cozzi R; Dallabonzana D; Oppizzi G; Verde G; Petroncini M; Liuzzi A; del Pozo E J Clin Endocrinol Metab; 1987 Mar; 64(3):447-53. PubMed ID: 2880861 [TBL] [Abstract][Full Text] [Related]
3. Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation. Oppizzi G; Petroncini MM; Dallabonzana D; Cozzi R; Verde G; Chiodini PG; Liuzzi A J Clin Endocrinol Metab; 1986 Dec; 63(6):1348-53. PubMed ID: 2878007 [TBL] [Abstract][Full Text] [Related]
4. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly. Quabbe HJ; Plöckinger U J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912 [TBL] [Abstract][Full Text] [Related]
5. Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995. Barkan AL; Kelch RP; Hopwood NJ; Beitins IZ J Clin Endocrinol Metab; 1988 Jan; 66(1):16-23. PubMed ID: 2891720 [TBL] [Abstract][Full Text] [Related]
6. The response of serum growth hormone levels to the long-acting somatostatin analog SMS 201-995 in acromegaly. Comi RJ; Gorden P J Clin Endocrinol Metab; 1987 Jan; 64(1):37-42. PubMed ID: 2878009 [TBL] [Abstract][Full Text] [Related]
7. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses. Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339 [TBL] [Abstract][Full Text] [Related]
8. The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. Lamberts SW; Oosterom R; Neufeld M; del Pozo E J Clin Endocrinol Metab; 1985 Jun; 60(6):1161-5. PubMed ID: 2860119 [TBL] [Abstract][Full Text] [Related]
9. Dynamics of the acute effects of octreotide, bromocriptine and both drugs in combination on growth hormone secretion in acromegaly. Wagenaar AH; Harris AG; van der Lely AJ; Lamberts SW Acta Endocrinol (Copenh); 1991 Dec; 125(6):637-42. PubMed ID: 1789059 [TBL] [Abstract][Full Text] [Related]
10. A comparison between the effects of SMS 201-995, bromocriptine and a combination of both drugs on hormone release by the cultured pituitary tumour cells of acromegalic patients. Lamberts SW; Verleun T; Hofland L; Del Pozo E Clin Endocrinol (Oxf); 1987 Jul; 27(1):11-23. PubMed ID: 2888550 [TBL] [Abstract][Full Text] [Related]
11. Somatostatin analog treatment of acromegaly: new aspects. Lamberts SW; del Pozo E Horm Res; 1988; 29(2-3):115-7. PubMed ID: 2900190 [TBL] [Abstract][Full Text] [Related]
12. A randomized study of SMS 201-995 versus bromocriptine treatment in acromegaly: clinical and biochemical effects. Halse J; Harris AG; Kvistborg A; Kjartansson O; Hanssen E; Smiseth O; Djøsland O; Hass G; Jervell J J Clin Endocrinol Metab; 1990 May; 70(5):1254-61. PubMed ID: 2186055 [TBL] [Abstract][Full Text] [Related]
13. Treatment with octreotide and bromocriptine in patients with acromegaly: an open pharmacodynamic interaction study. Fredstorp L; Kutz K; Werner S Clin Endocrinol (Oxf); 1994 Jul; 41(1):103-8. PubMed ID: 8050122 [TBL] [Abstract][Full Text] [Related]
14. The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly. Lamberts SW; Zweens M; Klijn JG; van Vroonhoven CC; Stefanko SZ; Del Pozo E Clin Endocrinol (Oxf); 1986 Aug; 25(2):201-12. PubMed ID: 2878748 [TBL] [Abstract][Full Text] [Related]
15. The effect of subcutaneous infusion versus subcutaneous injections of a somatostatin analogue (SMS 201-995) on the diurnal GH profile in acromegaly. Timsit J; Chanson P; Larger E; Duet M; Mosse A; Guillausseau PJ; Harris AG; Moulonguet M; Warnet A; Lubetzki J Acta Endocrinol (Copenh); 1987 Sep; 116(1):108-12. PubMed ID: 2889306 [TBL] [Abstract][Full Text] [Related]
16. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years. Lamberts SW; Uitterlinden P; del Pozo E J Clin Endocrinol Metab; 1987 Oct; 65(4):703-10. PubMed ID: 2888785 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the effectiveness of 2-hourly versus 8-hourly subcutaneous injections of a somatostatin analog (SMS 201-995) in the treatment of acromegaly. Wang C; Lam KS; Arceo E; Chan FL J Clin Endocrinol Metab; 1989 Sep; 69(3):670-7. PubMed ID: 2668325 [TBL] [Abstract][Full Text] [Related]
19. A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly. Fløgstad AK; Halse J; Grass P; Abisch E; Djøseland O; Kutz K; Bodd E; Jervell J J Clin Endocrinol Metab; 1994 Aug; 79(2):461-5. PubMed ID: 8045964 [TBL] [Abstract][Full Text] [Related]